Buying months matters in a disease this aggressive
Among the most resistant forms of breast cancer, triple-negative disease has long confronted patients and physicians alike with a narrowing corridor of options. Researchers at Mount Sinai have now found that pairing the drug everolimus with standard carboplatin chemotherapy may widen that corridor, cutting the risk of disease progression or death by more than half in a phase 2 trial. The discovery turns on a missing gene — PTEN — whose absence leaves a cellular growth pathway unchecked, and which everolimus is designed to quiet. The finding is preliminary, but in a disease where time and options are both scarce, it represents a meaningful step forward.
- Triple-negative breast cancer, affecting one in ten breast cancer patients, is among the most aggressive forms of the disease and resists most targeted therapies — leaving many patients with rapidly shrinking options.
- A phase 2 trial at Mount Sinai found that adding everolimus to carboplatin chemotherapy cut the risk of progression or death by 52%, a striking result in a disease where incremental gains are hard-won.
- The biological logic is precise: many triple-negative tumors lack the PTEN gene, causing the mTOR growth pathway to run unchecked, and everolimus acts as a molecular brake on exactly that mechanism.
- Crucially, the combination was well tolerated — a rare and important quality in advanced cancer treatment, where side effects can force patients to abandon therapies that might otherwise help them.
- Researchers caution that phase 3 trials involving larger patient populations are still required before this regimen can be considered a standard of care for metastatic triple-negative breast cancer.
At the Icahn School of Medicine at Mount Sinai, researchers have identified a drug combination that may meaningfully slow one of the most difficult-to-treat cancers. In a randomized phase 2 trial, patients with advanced triple-negative breast cancer who received everolimus alongside carboplatin chemotherapy saw a 52 percent reduction in their risk of disease progression or death compared to those receiving chemotherapy alone — and the regimen was well tolerated throughout.
Triple-negative breast cancer accounts for roughly ten to fifteen percent of diagnoses but is disproportionately dangerous. It lacks the receptors that make other breast cancers vulnerable to targeted therapies, leaving physicians with fewer tools and patients facing faster resistance to standard approaches. The new combination targets a specific biological vulnerability: many triple-negative tumors are missing the PTEN gene, which normally restrains cell growth. Without it, the mTOR pathway accelerates cancer proliferation unchecked. Everolimus blocks this pathway, and the trial — enrolling patients who had already undergone up to three prior rounds of treatment — showed that those receiving the combination remained progression-free longer than those on chemotherapy alone.
Senior author Dr. Amy Tiersten noted that the tolerability of the regimen is as significant as its efficacy — a combination that works but proves too toxic offers little real benefit to patients already carrying the weight of advanced disease. First author Dr. Rima Patel was careful to frame the results as promising but preliminary. Larger phase 3 trials will be needed to confirm the benefit across broader populations before carboplatin and everolimus can be established as a standard option. If those trials succeed, the combination could offer patients a meaningful extension of progression-free time in a disease where such gains are rare. The study was supported by Novartis, the manufacturer of everolimus.
Researchers at the Icahn School of Medicine at Mount Sinai have identified a drug combination that appears to slow the progression of triple-negative breast cancer, one of the most stubborn and dangerous forms of the disease. In a randomized phase 2 trial published in Breast Cancer Research and Treatment, patients who received everolimus alongside the standard chemotherapy drug carboplatin experienced a 52 percent reduction in their risk of disease progression or death compared to those given carboplatin alone. The treatment was well tolerated, with no unexpected safety problems emerging during the study.
Triple-negative breast cancer accounts for roughly one in ten breast cancer diagnoses, but it punches above its weight in terms of difficulty. Unlike other breast cancers, it lacks three key receptors that make tumors vulnerable to existing targeted therapies, which means doctors have fewer tools in their arsenal. The disease is often more aggressive and harder to treat than other breast cancer types, and many patients find their options narrowing quickly as their cancer develops resistance to standard approaches.
The biological mechanism behind the new finding centers on a missing gene called PTEN. Many triple-negative tumors lack this gene, which normally acts as a brake on cell growth. Without it, a cellular growth pathway called mTOR becomes hyperactive, essentially pressing the accelerator on cancer proliferation. Everolimus works by blocking this mTOR pathway, potentially slowing or halting the cancer's spread. The Mount Sinai team tested this theory in patients whose triple-negative cancers had already been treated multiple times—up to three prior rounds of therapy. Some patients received carboplatin chemotherapy alone, while others received the same chemotherapy paired with everolimus. Those in the combination group stayed free of disease progression longer than those treated with chemotherapy only.
Dr. Amy Tiersten, a senior author on the study, noted that the findings suggest carboplatin and everolimus could offer a meaningful new path for patients who have exhausted other options. The regimen's tolerability is significant; in cancer treatment, a drug combination that works but causes severe side effects can be difficult for patients to endure. Here, the safety profile remained clean, suggesting the approach might be sustainable for people already dealing with the burden of advanced cancer.
Dr. Rima Patel, the study's first author, emphasized that the results are promising but preliminary. The phase 2 trial, while encouraging, is a relatively small step in the drug development process. Larger phase 3 studies will be necessary to confirm that the benefit holds up in a broader patient population and to establish whether carboplatin and everolimus should become a standard treatment option for metastatic triple-negative breast cancer. If those larger trials succeed, the combination could offer patients an alternative to single-agent chemotherapy, potentially extending the time they live without their disease advancing—a meaningful gain in a disease where options are limited. The work was supported by Novartis, which manufactures everolimus.
Citações Notáveis
This combination could represent a promising new treatment option for advanced triple-negative breast cancer if validated in phase 3 trials.— Dr. Rima Patel, first author, Icahn School of Medicine
The combination of carboplatin and everolimus could offer a new option for patients, and should be further tested in larger clinical trials to confirm its effectiveness and safety.— Dr. Amy Tiersten, senior author, Icahn School of Medicine
A Conversa do Hearth Outra perspectiva sobre a história
Why does triple-negative breast cancer get its name, and what makes it so much harder to treat?
It's called triple-negative because the cancer cells lack three receptors—estrogen, progesterone, and HER2—that doctors can usually target with drugs. Without those handles to grab onto, the standard targeted therapies don't work. You're left with chemotherapy, which is blunt and toxic.
So everolimus is attacking a different vulnerability altogether?
Exactly. Most triple-negative tumors are missing the PTEN gene, which normally keeps cell growth in check. Without it, a growth pathway called mTOR runs wild. Everolimus blocks that pathway. It's like finding a different door into the same problem.
The 52 percent reduction in progression risk—what does that actually mean for a patient's life?
It means the time before their cancer starts growing again gets longer. In a disease this aggressive, buying months matters. It's not a cure, but it's a reprieve, and for people who've already tried multiple treatments, that's significant.
Why do they need phase 3 trials if phase 2 already showed this benefit?
Phase 2 is proof of concept with a smaller group. Phase 3 tests it in hundreds more patients to make sure the effect is real and consistent, not a fluke. It's the difference between a promising signal and something doctors can actually rely on.
What happens to patients right now, before phase 3 is done?
They're still limited to the options that exist today. If this trial's results hold up, it could become another tool in the toolkit within a few years. But for now, it's hope on the horizon, not yet in hand.